<DOC>
	<DOC>NCT00216411</DOC>
	<brief_summary>The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.</brief_summary>
	<brief_title>Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>The patient has suffered a stroke, as defined by the World Health Organisation (WHO) criteria, at least 6 months previously. The patient has a hemiparetic arm and meets minimum score requirements on the Modified Ashworth Scale. The patient has the cognitive and communication ability to participate in the study. Patients who have received botulinum toxin treatment within the past 120 days. Contraindication to botulinum toxin treatment. Patients who are receiving oral antispasticity medication and who have had a change in dosage of this medication in the month prior to study entry. Patients who have previously been treated with phenol for their upper limb spasticity.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>